Viridian Therapeutics Inc
VRDN
Company Profile
Business description
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
Contact
221 Crescent Street
Suite 103A
WalthamMA02453
USAT: +1 617 272-4600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
252
Stocks News & Analysis
stocks
Higher credit stress for big four bank
Shares fall after announcement that capital will be replenished for loan impairment provisions.
stocks
The ASX player evolving into a defensive haven
A well-timed simplification journey as boring evolves back in vogue.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,177.10 | 16.10 | -0.18% |
| CAC 40 | 8,311.82 | 19.22 | -0.23% |
| DAX 40 | 24,504.27 | 86.47 | 0.35% |
| Dow JONES (US) | 49,442.56 | 4.87 | -0.01% |
| FTSE 100 | 10,588.51 | 20.57 | -0.19% |
| HKSE | 26,487.48 | 126.41 | 0.48% |
| NASDAQ | 24,404.39 | 64.09 | -0.26% |
| Nikkei 225 | 59,349.17 | 873.27 | 1.49% |
| NZX 50 Index | 12,932.33 | 26.66 | 0.21% |
| S&P 500 | 7,109.14 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,949.40 | 20.10 | -0.22% |
| SSE Composite Index | 4,085.08 | 2.95 | 0.07% |